Stockscreener 앱 받기
162.80
2.09%
-3.48
시간 외 거래:
162.51
-0.29
-0.18%
전일 마감가:
$166.28
열려 있는:
$166.51
하루 거래량:
228.79K
Relative Volume:
1.10
시가총액:
$6.53B
수익:
-
순이익/손실:
$-77.61M
주가수익비율:
-70.85
EPS:
-2.2979
순현금흐름:
-
1주 성능:
-0.15%
1개월 성능:
+10.99%
6개월 성능:
-7.11%
1년 성능:
+136.01%
1일 변동 폭
$159.00
$167.00
1주일 범위
$159.00
$181.56
52주 변동 폭
$60.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
162.80 | 7.17B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 개시 | BofA Securities | Buy |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-02 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 개시 | Mizuho | Neutral |
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
모두보기
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio CFO Hao-Yuan Chuang Sells 367 ADS Under Rule 10b5-1 Plan - Kalkine Media
Belite Bio CEO Lin Yu-Hsin Reports Sale of 365 ADS Under Rule 10b5-1 Plan - Kalkine Media
Benchmark reiterates Belite Bio stock rating on FDA priority review - Investing.com
Benchmark reiterates Belite Bio stock rating on FDA priority review By Investing.com - Investing.com Canada
Mizuho raises Belite Bio stock price target to $220 on NDA progress - Investing.com
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares By Investing.com - Investing.com South Africa
Hao-Yuan Chuang Sells 367 Shares of Belite Bio (NASDAQ:BLTE) Stock - marketbeat.com
Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock - marketbeat.com
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares - Investing.com
Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000 - Investing.com Nigeria
Belite Bio (BLTE) Could Be 21% Below Fair Value As FDA Priority Review Lands - Sahm
Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ... By GuruFocus - Investing.com Canada
Belite Bio Q2 2026 Earnings Call Transcript - marketbeat.com
Belite Bio Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips - Investing.com
Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2%Should You Sell? - marketbeat.com
Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS - marketbeat.com
Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out - TipRanks
Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss - Stock Titan
Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease - Sahm
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update - The Manila Times
BLTE (NASDAQ: BLTE) files Form 144 for 93,800 ADS sale - Stock Titan
Yi Chen Raises Approval Odds and Lifts Tinlarebant-Focused 12‑Month Price Target to $214 While Reiterating Buy Rating - TipRanks
Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review - Investing.com Nigeria
Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook - Investing.com
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA - TradingView
HC Wainwright Issues Positive Forecast for Belite Bio (NASDAQ:BLTE) Stock Price - marketbeat.com
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease - TipRanks
FDA grants priority review for Belite Bio’s Stargardt treatment By Investing.com - Investing.com Nigeria
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
Belite Bio (NASDAQ: BLTE) wins FDA priority review for tinlarebant in Stargardt disease - Stock Titan
Belite Bio (BLTE) Short Interest & Short Float | Updated Aug 2026 $BLTE - marketbeat.com
How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing - Stock Traders Daily
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - marketbeat.com
The Manufacturers Life Insurance Company Purchases New Shares in Belite Bio, Inc. Sponsored ADR $BLTE - marketbeat.com
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results - markets.businessinsider.com
Renaissance Technologies LLC Makes New Investment in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
Belite Bio (BLTE) Expected to Post Quarterly Earnings on Monday - MarketBeat
Perceptive Advisors LLC Has $24.23 Million Stock Position in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
ADAR1 Capital Management LLC Sells 12,959 Shares of Belite Bio, Inc. Sponsored ADR $BLTE - marketbeat.com
(BLTE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Price to sales forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
Belite Bio, Inc. ADR Revenue Breakdown – FWB:D01 - TradingView
Belite Bio, Inc. Sponsored ADR $BLTE Shares Acquired by Affinity Asset Advisors LLC - marketbeat.com
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases - MarketBeat
Belite Bio stock price target maintained at $200 by H.C. Wainwright - Investing.com UK
Belite Bio stock price target maintained at $200 by H.C. Wainwright By Investing.com - Investing.com Australia
Belite Bio presents additional Phase 3 trial data for tinlarebant By Investing.com - Investing.com South Africa
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 - The Manila Times
Belite Bio presents additional Phase 3 trial data for tinlarebant - Investing.com
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):